Two Gujarat COVID-19 Patients Treated With Plasma Therapy Show Incredible Improvement
Harin
Two COVID-19 patients treated at the Ahmedabad-based SVP Hospital have received plasma therapy with two doses of 200ml convalescent plasma.
- This Man's Super-Antibody Can Be Diluted 10,000 Times But Still Works Against COVID-19
- These Indian Cities Are Under Lockdown Again In 2021
- India To Review Covishield Vaccine After Report Of Blood Clots Following Vaccination
Plasma Therapy could be a game-changer in the battle against COVID-19 as patients who have undergone the treatment have shown incredible improvement.
Gujarat has become India’s latest state to use plasma therapy to treat COVID-19 patients.
Two patients who are receiving treatment at the Ahmedabad-based SVP Hospital have received plasma therapy. At the moment, the conditions of them are stable, according to Jayanti Ravi, Principal Health Secretary.
The two patients received two doses of 200ml convalescent plasma. Each dose is from a recovered patient. A 24-year-old discharged on April 6 was the first donor while a 34-year-old woman discharged on March 29 was the second donor.
Earlier, a 49-year-old patient from Delhi treated using plasma therapy at the Max Hospital has also shown significant improvement. He doesn’t need to use the ventilator anymore. His results for COVID-19 test have been negative for two times.
Public hospitals have received permission from the Indian Council of Medical Research to conduct clinical trials on infected patients to test convalescent plasma’s therapy safety and efficacy.
Sree Chitra Tirunal Institute for Medical Sciences and Technology’s Director, Dr. Asha Kishore, stated that the ICMR has called for a multi-center clinical trial across the country as well as publishing an ICMR protocol approved by DCGI.
This proposal’s goal is to study how convalescent plasma therapy affects moderate COVID-19 cases.
COVID-19 hospitals with blood banks that meet the trial’s eligibility criteria can apply to ICMR.
She said:
SCTIMST is an institute under the Department of Science and Technology. The ICMR had given clearances for SCTIMST to conduct clinical trials for convalescent plasma therapy. The therapy uses antibodies taken from the blood of a recovered patient. These antibodies are then used to treat another patient.
Up until now, the therapy has been used to treat critical patients. Now, it will be tested on patients with moderate conditions.